# US Biologics Safety Testing Market

> United States Biologics Safety Testing Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.02%
- **2024:** $ 850 Million
- **2025:** $ 969.17 Million
- **2035:** $ 3,600 Million
- **Key Players:** Charles River Laboratories (US), Eurofins Scientific (FR), Sartorius AG (DE), Merck KGaA (DE), Lonza Group (CH), WuXi AppTec (CN), Thermo Fisher Scientific (US), SGS SA (CH)

**Report ID:** MRFR/LS/13115-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biologics-safety-testing-market-14642

---

## Market Summary

## US Biologics Safety Testing Market Highlighted Trends & Dynamics

The demand for Biologics Safety Testing in the United States has seen significant growth, driven by the expanding biopharmaceutical industry and the increasing importance of ensuring the safety and efficacy of biologic drugs. Biologics, which include therapeutic proteins, monoclonal antibodies, and vaccines, require rigorous safety testing throughout their development and production processes. The U.S. Biologics Safety Testing market has evolved to meet these demands, playing a critical role in maintaining the high standards required for the approval and release of biopharmaceutical products.

One of the primary drivers behind the escalating demand for Biologics Safety Testing is the robust growth of the biopharmaceutical industry. Biologics, with their complex structures and mechanisms of action, have become essential in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. As the number of biologic drug candidates in development and on the market continues to rise, there is an increasing need for comprehensive safety testing to ensure the quality, purity, and safety of these products.

Biologics Safety Testing encompasses a range of assays and evaluations, including tests for identity, potency, purity, and the absence of contaminants.

The regulatory landscape and stringent quality standards set by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have played a pivotal role in shaping the demand for Biologics Safety Testing. Regulatory authorities require thorough safety assessments of biologic drugs at various stages of development and production to safeguard patient health. Biologics Safety Testing ensures compliance with regulatory guidelines and standards, including Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP), contributing to the successful approval and commercialization of biopharmaceutical products.

The complexity of biologic drugs, derived from living cells or organisms, necessitates a multifaceted approach to safety testing. Cell-based assays, analytical techniques, and molecular biology methods are integral components of Biologics Safety Testing. Cell-based assays evaluate the biological activity, potency, and potential immunogenicity of biologics, while analytical techniques, such as mass spectrometry and chromatography, assess the composition and purity of the products. The stringent safety testing protocols address potential risks, including contamination, impurities, and unintended immunogenic responses, ensuring the overall safety profile of biologic drugs.

Advancements in technology and methodologies have played a crucial role in enhancing the efficiency and accuracy of Biologics Safety Testing. High-throughput screening, next-generation sequencing, and advanced analytics have become integral to the safety assessment process. These technologies enable the simultaneous evaluation of multiple parameters, allowing for a more comprehensive understanding of the safety profile of biologic drugs. The integration of cutting-edge technologies into Biologics Safety Testing reflects the industry's commitment to continuous improvement and staying at the forefront of scientific advancements.

The competitive landscape of the U.S. Biologics Safety Testing market includes a mix of contract testing organizations, in-house testing facilities of biopharmaceutical companies, and specialized testing service providers. Major players offer a range of testing services, including bioanalytical testing, microbiology testing, and viral safety testing, tailored to the specific needs of biologic drug developers. Collaborations between testing service providers and biopharmaceutical companies are common, allowing for the customization and integration of safety testing solutions throughout the drug development life cycle.

## Market Drivers

### Rising Demand for Biologics

The increasing prevalence of chronic diseases and the aging population in the US are driving the demand for biologics. As biologics are often more effective than traditional pharmaceuticals, their usage is expanding. This trend is likely to boost the biologics safety-testing market, as rigorous testing is essential to ensure the safety and efficacy of these products. In 2024, the biologics segment accounted for approximately 30% of the total pharmaceutical market, indicating a substantial market share. Consequently, the need for comprehensive safety testing protocols is becoming more pronounced, as stakeholders seek to mitigate risks associated with biologic therapies.

### Stringent Regulatory Frameworks

The biologics safety-testing market is significantly influenced by the stringent regulatory frameworks established by agencies such as the FDA. These regulations mandate comprehensive safety testing for biologics before they can be approved for public use. The emphasis on patient safety and product efficacy has led to the implementation of more rigorous testing protocols. As regulatory bodies continue to evolve their guidelines, the demand for compliance in the biologics safety-testing market is expected to rise. This trend underscores the importance of maintaining high safety standards, which is crucial for gaining regulatory approval and ensuring market access.

### Growing Awareness of Patient Safety

There is a growing awareness among healthcare professionals and patients regarding the importance of safety in biologics. This heightened awareness is driving demand for thorough safety testing to ensure that biologic therapies do not pose risks to patients. As patients become more informed about their treatment options, they are increasingly advocating for transparency and safety in the biologics they receive. This trend is likely to influence the biologics safety-testing market, as companies strive to meet the expectations of both regulators and consumers. The focus on patient safety is expected to shape the future of biologics development and testing.

### Advancements in Testing Technologies

Technological innovations in the biologics safety-testing market are transforming the landscape of safety assessments. The introduction of high-throughput screening and advanced analytical techniques enhances the accuracy and efficiency of testing processes. For instance, the adoption of next-generation sequencing (NGS) has revolutionized the way biologics are evaluated for safety. These advancements not only reduce testing timelines but also improve the reliability of results. As a result, companies are increasingly investing in state-of-the-art testing technologies, which is expected to propel the growth of the biologics safety-testing market in the coming years.

### Increased Investment in Research and Development

The biologics safety-testing market is experiencing a surge in investment as pharmaceutical companies prioritize research and development (R&D) to innovate new biologic therapies. In 2025, R&D spending in the biopharmaceutical sector is projected to reach $200 billion, reflecting a commitment to developing safer and more effective biologics. This influx of funding is likely to enhance the capabilities of safety-testing laboratories, enabling them to conduct more comprehensive assessments. As a result, the biologics safety-testing market is poised for growth, driven by the need for rigorous safety evaluations in the face of increasing R&D activities.

## Future Outlook

The [Biologics Safety Testing Market](https://www.marketresearchfuture.com/reports/biologics-safety-testing-market-6800) is projected to grow at a 14.02% CAGR from 2025 to 2035, driven by increasing regulatory demands and technological advancements.

**New opportunities:**

- Development of automated testing platforms for enhanced efficiency.
- 
- Expansion of contract testing services to meet diverse client needs.
- Investment in AI-driven analytics for predictive safety assessments.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Testing Type: Sterility Testing (Largest) vs. Endotoxin Testing (Fastest-Growing)

Within the US biologics safety-testing market, Sterility Testing remains the largest segment, driven by its critical role in ensuring product safety and regulatory compliance. Endotoxin Testing, although smaller in market share compared to Sterility Testing, is rapidly gaining traction due to increased demand for endotoxin-free products, particularly in the development of biologics and pharmaceuticals.

The growth trends within this segment are significant, as regulatory agencies heighten the standards for safety testing. The surge in biologics research and development, alongside the rise in healthcare-associated infections, has fueled demand for both Sterility and Endotoxin Testing. Additionally, technological advancements have improved testing efficiency, which is expected to drive further adoption, particularly for Endotoxin Testing, which is poised to become a leading area of innovation in the industry.

Sterility Testing (Dominant) vs. Bioburden Testing (Emerging)

Sterility Testing is recognized as the dominant force in the market, primarily due to its established protocols and necessity in validating the absence of viable microorganisms in biologics. This segment plays a vital role in ensuring compliance with stringent regulatory requirements. In contrast, Bioburden Testing is an emerging segment that measures the number of viable microorganisms present in a sample, serving as a preliminary test before sterility testing. As biopharmaceutical companies seek to optimize product safety, Bioburden Testing is gaining attention for its ability to provide earlier detection of microbial contamination. Together, these segments illustrate a comprehensive approach to microbial testing, with Sterility Testing leading the way while Bioburden Testing sets the stage for proactive safety measures.

### By Product Type: Reagents (Largest) vs. Kits (Fastest-Growing)

In the US biologics safety-testing market, the distribution among product types reveals that reagents hold the largest share, reflecting their essential role in various testing protocols. Kits, while currently smaller in share, are gaining traction and are becoming increasingly popular due to their convenience and comprehensive solutions for testing needs.

Growth trends in this segment are primarily driven by increased regulatory requirements and a rising demand for rapid testing solutions. The trend towards automation and the development of more sophisticated testing kits are propelling the expansion of the kits segment. Additionally, advancements in biotechnology and an emphasis on quality assurance in biologics safety testing continue to enhance the demand for reagents.

Reagents (Dominant) vs. Kits (Emerging)

Reagents are a dominant force in the US biologics safety-testing market, as they serve as fundamental components for numerous testing applications, enabling precise measurement and analysis. Their versatile nature makes them indispensable for laboratories focusing on safety and efficacy. On the other hand, kits are emerging as a significant player, drawing attention for their user-friendly designs and all-in-one solutions, making testing accessible to a wider range of facilities. This shift in preference is reflective of the market's evolution towards more integrated and efficient testing solutions that meet the diverse needs of the healthcare ecosystem.

### By Application: Vaccine Development (Largest) vs. Therapeutics (Fastest-Growing)

The market share distribution of the application segment in the US biologics safety-testing market reveals that Vaccine Development holds the largest share, attributed to the increased global focus on immunization, especially in the wake of recent health crises. Therapeutics follows closely, demonstrating significant interest from pharmaceutical companies as they endeavor to validate and ensure the safety of various biologic therapies through safety testing frameworks. 

Growth trends in this segment are particularly driven by a surge in demand for safer and more effective therapeutics, combined with ongoing innovations in vaccine research and development. The regulatory landscape also plays a critical role in shaping these trends, as stringent safety requirements necessitate robust testing protocols for both vaccines and therapeutics, thereby propelling the market forward.

Vaccine Development (Dominant) vs. Cellular and Gene Therapy (Emerging)

Vaccine Development stands as the dominant application in the US biologics safety-testing market, characterized by a well-established framework and extensive historical data supporting its efficacy. The focus here is primarily on ensuring the safety and efficacy of vaccines as they undergo rigorous testing before public administration. On the other hand, Cellular and Gene Therapy represents an emerging application, showcasing rapid advancements and increasing investments as researchers and manufacturers look to harness the potential of gene editing and regenerative medicine. While the former benefits from proven methodologies, the latter is rapidly evolving, requiring innovative safety-testing approaches tailored to the unique challenges posed by genetic manipulation.

### By End-Use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the US biologics safety-testing market, Pharmaceutical Companies hold the largest market share, driven by their high demand for safety testing in drug development and approval processes. These companies require rigorous and comprehensive testing protocols to ensure the efficacy and safety of biologic products, contributing significantly to their prominence in this market segment.

On the other hand, Biotechnology Companies are emerging as the fastest-growing segment, reflecting the increasing investment in biopharmaceutical innovations. As these companies continue to develop novel biologics, their need for specialized testing services is rapidly expanding, resulting in a notable acceleration in their market share and prominence in the industry.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical Companies are dominant in the US biologics safety-testing market due to their established infrastructure and extensive experience in product testing. They invest heavily in compliance with regulatory standards, ensuring that safety protocols are meticulously followed. Meanwhile, Biotechnology Companies represent an emerging force, characterized by their agility and innovative approach to drug development. They focus on cutting-edge therapies and often require customized testing solutions tailored to their novel product lines. The collaboration between these two segments drives advancements in the safety testing landscape, as pharmaceutical giants often partner with biotech firms to integrate new technologies.

## Competitive Benchmarking

The biologics safety-testing market is characterized by a dynamic competitive landscape, driven by increasing regulatory scrutiny and the growing demand for biologics in therapeutic applications. Key players such as Charles River Laboratories (US), Thermo Fisher Scientific (US), and Lonza Group (CH) are strategically positioned to leverage their extensive service portfolios and technological advancements. Charles River Laboratories (US) focuses on innovation through its investment in advanced testing methodologies, while Thermo Fisher Scientific (US) emphasizes digital transformation to enhance operational efficiency. Lonza Group (CH) is actively pursuing partnerships to expand its capabilities in biologics testing, thereby shaping a competitive environment that prioritizes quality and compliance.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. This fragmentation allows for a diverse range of services, catering to various client needs. The collective influence of these key players fosters a competitive atmosphere where innovation and service quality are paramount, as companies strive to differentiate themselves in a crowded marketplace.
In October Thermo Fisher Scientific (US) announced the launch of a new suite of biologics testing services aimed at accelerating drug development timelines. This strategic move is significant as it aligns with the industry's increasing demand for faster and more reliable testing solutions, potentially enhancing the company's market position and attracting new clients seeking expedited services.
In September Charles River Laboratories (US) expanded its biologics testing capabilities by acquiring a specialized laboratory in California. This acquisition is likely to bolster its service offerings and geographic reach, enabling the company to better serve its clients in the rapidly evolving biologics sector. Such strategic expansions are indicative of a broader trend where companies seek to enhance their operational footprint to meet growing market demands.
In August Lonza Group (CH) entered into a strategic partnership with a leading biotech firm to co-develop innovative testing solutions for biologics. This collaboration underscores the importance of strategic alliances in fostering innovation and addressing the complexities of biologics safety testing. By pooling resources and expertise, both companies may enhance their competitive edge and drive advancements in testing methodologies.
As of November the competitive trends in the biologics safety-testing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into testing processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating regulatory challenges and technological advancements. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological integration, and supply chain reliability, as companies strive to meet the demands of a rapidly changing market.

## Report Scope

| MARKET SIZE 2024 | 850.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 969.17(USD Million) |
| MARKET SIZE 2035 | 3600.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.02% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Charles River Laboratories (US), Eurofins Scientific (FR), Sartorius AG (DE), Merck KGaA (DE), Lonza Group (CH), WuXi AppTec (CN), Thermo Fisher Scientific (US), SGS SA (CH) |
| Segments Covered | Testing Type, Product Type, Application, End-Use |
| Key Market Opportunities | Integration of advanced technologies enhances efficiency in the biologics safety-testing market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation in the biologics safety-testing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US biologics safety-testing market in 2024?**
A: The market valuation was $850.0 Million in 2024.

**Q: What is the projected market valuation for the US biologics safety-testing market by 2035?**
A: The projected valuation for 2035 is $3600.0 Million.

**Q: What is the expected CAGR for the US biologics safety-testing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 14.02% during the forecast period 2025 - 2035.

**Q: Which testing types are included in the US biologics safety-testing market, and what were their valuations in 2024?**
A: Testing types include Sterility Testing at $740.0 Million, Endotoxin Testing at $850.0 Million, Bioburden Testing at $600.0 Million, and Validation Testing at $1210.0 Million.

**Q: What product types are part of the US biologics safety-testing market, and what were their valuations in 2024?**
A: Product types include Reagents at $850.0 Million, Kits at $1200.0 Million, and Services at $1550.0 Million.

**Q: What applications are covered in the US biologics safety-testing market, and what were their valuations in 2024?**
A: Applications include Vaccine Development at $800.0 Million, Therapeutics at $1000.0 Million, Blood and Blood Products at $600.0 Million, and Cellular and Gene Therapy at $1200.0 Million.

**Q: Who are the key players in the US biologics safety-testing market?**
A: Key players include Charles River Laboratories, Eurofins Scientific, Sartorius AG, Merck KGaA, Lonza Group, WuXi AppTec, Thermo Fisher Scientific, and SGS SA.

**Q: What end-use segments are present in the US biologics safety-testing market, and what were their valuations in 2024?**
A: End-use segments include Pharmaceutical Companies at $1500.0 Million, Biotechnology Companies at $1500.0 Million, and Research Institutions at $600.0 Million.

**Q: How does the market size for services compare to other product types in the US biologics safety-testing market?**
A: Services, valued at $1550.0 Million, represent the largest segment compared to Reagents at $850.0 Million and Kits at $1200.0 Million.

**Q: What trends are anticipated in the US biologics safety-testing market as it approaches 2035?**
A: The market is likely to experience robust growth, driven by increasing demand for safety testing in biologics, with a projected valuation reaching $3600.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biologics-safety-testing-market-14642*